Global Biobanking Market Size, Share, Analysis, Forecast: By Material: Population-based Biobanks, Disease-based Biobanks, Academic Biobanks, Hospital-based Biobanks, Commercial Biobanks; By Sample Type: Blood Products, Others; By Application; By Ownership; By Source; By End User; Regional Analysis; Supplier Landscape; 2024-2032

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Global Biobanking Market Overview 
    3.1    Global Biobanking Market Historical Value (2017-2023) 
    3.2    Global Biobanking Market Forecast Value (2024-2032)
4    Global Biobanking Market Landscape*
    4.1    Global Biobanking: Developers Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Company Size
        4.1.3    Analysis by Region
    4.2    Global Biobanking: Product Landscape
        4.2.1    Analysis by Material    
        4.2.2    Analysis by Sample Type
5    Global Biobanking Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
        5.2.1    Strengths
        5.2.2    Weaknesses
        5.2.3    Opportunities
        5.2.4    Threats
    5.3    Porter’s Five Forces Model
        5.3.1    Bargaining Power of Suppliers
        5.3.2    Bargaining Power of Buyers
        5.3.3    Threat of New Entrants
        5.3.4    Threat of Substitutes
        5.3.5    Degree of Rivalry
    5.4    Key Demand Indicators 
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends  
    5.7    Value Chain Analysis
6    Global Biobanking Market Segmentation (2017-2032)
    6.1    Global Biobanking Market (2017-2032) by Material
        6.1.1    Market Overview    
        6.1.2    Population-based Biobanks
        6.1.3    Disease-based Biobanks
        6.1.4    Academic Biobanks
        6.1.5    Hospital-based Biobanks
        6.1.6    Commercial Biobanks
    6.2    Global Biobanking Market (2017-2032) by Sample Type
        6.2.1    Market Overview    
        6.2.2    Blood Products
        6.2.3    Human Tissues
        6.2.4    Nucleic Acids
        6.2.5    Cell Lines
        6.2.6    Biological Fluids
        6.2.7    Others
    6.3    Global Biobanking Market (2017-2032) by Application
        6.3.1    Market Overview    
        6.3.2    Drug Discovery and Development
        6.3.3    Personalized Medicine
        6.3.4    Regenerative Medicine
        6.3.5    Clinical Research
        6.3.6    Forensics
        6.3.7    Others
    6.4    Global Biobanking Market (2017-2032) by Ownership
        6.4.1    Market Overview    
        6.4.2    Public Biobanks
        6.4.3    Private Biobanks
        6.4.4    Hybrid Biobanks
    6.5    Global Biobanking Market (2017-2032) by Source
        6.5.1    Market Overview
        6.5.2    Human Biobanks
        6.5.3    Animal Biobanks
        6.5.4    Plant Biobanks
    6.6    Global Biobanking Market (2017-2032) by End User
        6.6.1    Market Overview
        6.6.2    Biopharmaceutical Companies
        6.6.3    Research and Academic Institutes
        6.6.4    Hospitals
        6.6.5    Contract Research Organizations (CROs)
        6.6.6    Others
    6.7    Global Biobanking Market (2017-2032) by Region
        6.7.1    Market Overview
        6.7.2    North America
        6.7.3    Europe 
        6.7.4    Asia Pacific
        6.7.5    Latin America
        6.7.6    Middle East and Africa
7    North America Biobanking Market (2017-2032)
    7.1    North America Biobanking Market (2017-2032) by Material
        7.1.1    Market Overview    
        7.1.2    Population-based Biobanks
        7.1.3    Disease-based Biobanks
        7.1.4    Academic Biobanks
        7.1.5    Hospital-based Biobanks
        7.1.6    Commercial Biobanks
    7.2    North America Biobanking Market (2017-2032) by Sample Type
        7.2.1    Market Overview    
        7.2.2    Blood Products
        7.2.3    Human Tissues
        7.2.4    Nucleic Acids
        7.2.5    Cell Lines
        7.2.6    Biological Fluids
        7.2.7    Others
    7.3    North America Biobanking Market (2017-2032) by Country
        7.3.1    United States of America
        7.3.2    Canada
8    Europe Biobanking Market (2017-2032)
    8.1    Europe Biobanking Market (2017-2032) by Material
        8.1.1    Market Overview    
        8.1.2    Population-based Biobanks
        8.1.3    Disease-based Biobanks
        8.1.4    Academic Biobanks
        8.1.5    Hospital-based Biobanks
        8.1.6    Commercial Biobanks
    8.2    Europe Biobanking Market (2017-2032) by Sample Type
        8.2.1    Market Overview    
        8.2.2    Blood Products
        8.2.3    Human Tissues
        8.2.4    Nucleic Acids
        8.2.5    Cell Lines
        8.2.6    Biological Fluids
        8.2.7    Others
    8.3    Europe Biobanking Market (2017-2032) by Country
        8.3.1    United Kingdom
        8.3.2    Germany
        8.3.3    France
        8.3.4    Italy
        8.3.5    Others
9    Asia Pacific Biobanking Market (2017-2032)
    9.1    Asia Pacific Biobanking Market (2017-2032) by Material
        9.1.1    Market Overview    
        9.1.2    Population-based Biobanks
        9.1.3    Disease-based Biobanks
        9.1.4    Academic Biobanks
        9.1.5    Hospital-based Biobanks
        9.1.6    Commercial Biobanks
    9.2    Asia Pacific Biobanking Market (2017-2032) by Sample Type
        9.2.1    Market Overview    
        9.2.2    Blood Products
        9.2.3    Human Tissues
        9.2.4    Nucleic Acids
        9.2.5    Cell Lines
        9.2.6    Biological Fluids
        9.2.7    Others
    9.3    Asia Pacific Biobanking Market (2017-2032) by Country
        9.3.1    China
        9.3.2    Japan
        9.3.3    India
        9.3.4    ASEAN
        9.3.5    Australia
        9.3.6    Others
10    Latin America Biobanking Market (2017-2032)
    10.1     Latin America Biobanking Market (2017-2032) by Material
        10.1.1    Market Overview    
        10.1.2    Population-based Biobanks
        10.1.3    Disease-based Biobanks
        10.1.4    Academic Biobanks
        10.1.5    Hospital-based Biobanks
        10.1.6    Commercial Biobanks
    10.2     Latin America Biobanking Market (2017-2032) by Sample Type
        10.2.1    Market Overview    
        10.2.2    Blood Products
        10.2.3    Human Tissues
        10.2.4    Nucleic Acids
        10.2.5    Cell Lines
        10.2.6    Biological Fluids
        10.2.7    Others
    10.3     Latin America Biobanking Market (2017-2032) by Country
        10.3.1    Brazil
        10.3.2    Argentina
        10.3.3    Mexico
        10.3.4    Others
11    Middle East and Africa Biobanking Market (2017-2032)
    11.1     Middle East and Africa Biobanking Market (2017-2032) by Material
        11.1.1    Market Overview    
        11.1.2    Population-based Biobanks
        11.1.3    Disease-based Biobanks
        11.1.4    Academic Biobanks
        11.1.5    Hospital-based Biobanks
        11.1.6    Commercial Biobanks
    11.2     Middle East and Africa Biobanking Market (2017-2032) by Sample Type
        11.2.1    Market Overview    
        11.2.2    Blood Products
        11.2.3    Human Tissues
        11.2.4    Nucleic Acids
        11.2.5    Cell Lines
        11.2.6    Biological Fluids
        11.2.7    Others
    11.3     Middle East and Africa Biobanking Market (2017-2032) by Country
        11.3.1    Saudi Arabia
        11.3.2    United Arab Emirates
        11.3.3    Nigeria
        11.3.4    South Africa
        11.3.5    Others
12    Regulatory Framework
    12.1     Regulatory Overview
        12.1.1    US FDA
        12.1.2    EU EMA
        12.1.3    INDIA CDSCO
        12.1.4    JAPAN PMDA
        12.1.5    Others
13    Patent Analysis
    13.1     Analysis by Type of Patent
    13.2     Analysis by Publication Year
    13.3     Analysis by Issuing Authority
    13.4     Analysis by Patent Age
    13.5     Analysis by CPC Analysis
    13.6     Analysis by Patent Valuation 
    13.7     Analysis by Key Players
14    Grants Analysis
    14.1     Analysis by Year
    14.2     Analysis by Amount Awarded
    14.3     Analysis by Issuing Authority
    14.4     Analysis by Grant Application
    14.5     Analysis by Funding Institute
    14.6     Analysis by Departments
    14.7     Analysis by Recipient Organization 
15    Funding and Investment Analysis
    15.1     Analysis by Funding Instances
    15.2     Analysis by Type of Funding
    15.3     Analysis by Funding Amount
    15.4     Analysis by Leading Players
    15.5     Analysis by Leading Investors
    15.6     Analysis by Geography
16    Partnership  and Collaborations Analysis
    16.1     Analysis by Partnership Instances
    16.2     Analysis by Type of Partnership
    16.3     Analysis by Leading Players
    16.4     Analysis by Geography
17    Supplier Landscape
    17.1     Thermo Fisher Scientific Inc.
        17.1.1    Financial Analysis
        17.1.2    Product Portfolio
        17.1.3    Demographic Reach and Achievements
        17.1.4    Mergers and Acquisitions
        17.1.5    Certifications 
    17.2     Brooks Automation, Inc.
        17.2.1    Financial Analysis
        17.2.2    Product Portfolio
        17.2.3    Demographic Reach and Achievements
        17.2.4    Mergers and Acquisitions
        17.2.5    Certifications
    17.3     Qiagen N.V. 
        17.3.1    Financial Analysis
        17.3.2    Product Portfolio
        17.3.3    Demographic Reach and Achievements
        17.3.4    Mergers and Acquisitions
        17.3.5    Certifications
    17.4     Tecan Group Ltd.
        17.4.1     Financial Analysis
        17.4.2    Product Portfolio
        17.4.3    Demographic Reach and Achievements
        17.4.4    Mergers and Acquisitions
        17.4.5    Certifications
    17.5     Hamilton Company
        17.5.1    Financial Analysis
        17.5.2    Product Portfolio
        17.5.3    Demographic Reach and Achievements
        17.5.4    Mergers and Acquisitions
        17.5.5    Certifications
    17.6     Chart Industries, Inc.
        17.6.1    Financial Analysis
        17.6.2    Product Portfolio
        17.6.3    Demographic Reach and Achievements
        17.6.4    Mergers and Acquisitions
        17.6.5    Certifications
    17.7     PHC Holdings Corporation
        17.7.1    Financial Analysis
        17.7.2    Product Portfolio
        17.7.3    Demographic Reach and Achievements
        17.7.4    Mergers and Acquisitions
        17.7.5    Certifications
    17.8     Becton, Dickinson and Company (BD) 
        17.8.1    Financial Analysis
        17.8.2    Product Portfolio
        17.8.3    Demographic Reach and Achievements
        17.8.4    Mergers and Acquisitions
        17.8.5    Certifications
    17.9     Merck KGaA
        17.9.1    Financial Analysis
        17.9.2    Product Portfolio
        17.9.3    Demographic Reach and Achievements
        17.9.4    Mergers and Acquisitions
        17.9.5    Certifications
    17.10    Panasonic Healthcare Holdings Co., Ltd.
        17.10.1    Financial Analysis
        17.10.2    Product Portfolio
        17.10.3    Demographic Reach and Achievements
        17.10.4    Mergers and Acquisitions
        17.10.5    Certifications 
    17.11    STEMCELL Technologies Inc.
        17.11.1    Financial Analysis
        17.11.2    Product Portfolio
        17.11.3    Demographic Reach and Achievements
        17.11.4    Mergers and Acquisitions
        17.11.5    Certifications 
    17.12    Lifenet Health
        17.12.1    Financial Analysis
        17.12.2    Product Portfolio
        17.12.3    Demographic Reach and Achievements
        17.12.4    Mergers and Acquisitions
        17.12.5    Certifications 
    17.13    Promega Corporation
        17.13.1    Financial Analysis
        17.13.2    Product Portfolio
        17.13.3    Demographic Reach and Achievements
        17.13.4    Mergers and Acquisitions
        17.13.5    Certifications 
    17.14    Greiner Bio-One International GmbH
        17.14.1    Financial Analysis
        17.14.2    Product Portfolio
        17.14.3    Demographic Reach and Achievements
        17.14.4    Mergers and Acquisitions
        17.14.5    Certifications 
    17.15    Lonza Group AG
        17.15.1    Financial Analysis
        17.15.2    Product Portfolio
        17.15.3    Demographic Reach and Achievements
        17.15.4    Mergers and Acquisitions
        17.15.5    Certifications 
List not exhaustive
18    Global Biobanking  Market – Distribution Model (Additional Insight)
    18.1     Overview 
    18.2     Potential Distributors 
    18.3     Key Parameters for Distribution Partner Assessment 
19    Key Opinion Leaders (KOL) Insights (Additional Insight)
20    Company Competitiveness Analysis (Additional Insight)
    20.1     Very Small Companies
    20.2     Small Companies
    20.3     Mid-Sized Companies
    20.4     Large Companies
    20.5     Very Large Companies
21    Payment Methods (Additional Insight)
    21.1     Government Funded
    21.2     Private Insurance
    21.3     Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.